I know, and we have got partners. Gruenenthal and also Takeda is also there.
The latest funds are the means to and end though as it means this drives two phase 3 trials which are then FDA approvable products/cohorts.
That does mean more partnerships.
I don’t like the dilution here at all but it is done now. Moving on to better days.
Ann: Mesoblast Completes Placement and Entitlement Offer, page-49
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
0.005(0.54%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 93.0¢ | 93.5¢ | 91.5¢ | $1.473M | 1.596M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 32370 | 92.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.0¢ | 60258 | 5 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |